Vladimir Vladimirovich Zakharov

Vladimir Vladimirovich Zakharov

Auto-generated profile, based on publicly available information

Vladimir Vladimirovich Zakharov

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Dementia & Neuropsychologia
Verified
Journal Article
Open access
PDF file
VPVladimir Parfenov
Vladimir Parfenov
VZVladimir Vladimirovich Zakharov
Vladimir Vladimirovich Zakharov
AKAnastasia Romanovna Kabaeva
Anastasia Romanovna Kabaeva
NVNatalya Vasilyevna Vakhnina
Natalya Vasilyevna Vakhnina
Over 44 million people suffer from dementia around the world. Researchers estimated that there will be 48.1 million people with dementia by 2020 and 90.3 million by 2040. In addition to dementia, mild cognitive impairment (MCI) and subjective cognitive decline (SCD) relate to cognitive impairment. It has been established that MCI precedes dementia, however the significance of SCD is still unclear. Recent studies suggest that SCD could be a risk factor for objective cognitive impairment. SCD is defined as а self-estimated decline in cognitive capacity in comparison to an individual’s previous level of functioning, which cannot be determined by neuropsychological tests. Objectives: To perform a systematic review of prospective longitudinal cohort studies that assessed the risk of MCI and dementia among people with SCD. Methods: A search was carried out for all available peer-reviewed articles in English related to SCD in PubMed and PsychINFO databases from database initiation through January 2020. The keywords used for the search were ‘subjective cognitive (or memory) impairment (or decline or complaints)’. Three authors separately determined the inclusion or exclusion of all articles retrieved for full-text evaluation. Results: The chance of progression to dementia in the SCD group was 2.17 (95% confidence interval [95%CI] 1.53‒3.07; p<0.05) compared to normal aging. Furthermore, the SCD group was 2.15 times more likely to progress to MCI than the group without SCD (95%CI 1.39‒3.30; p=0.005). Conclusions: SCD might precede cognitive impairment, however, more detailed longitudinal studies should be conducted.

1 May 2017 in Stroke
Verified
Journal Article
Open access
PDF file
AGAlla Guekht
Alla Guekht
ISIngmar Skoog
Ingmar Skoog
SESally Edmundson
Sally Edmundson
VZVladimir Zakharov
Vladimir Zakharov
AKAmos D. Korczyn
Amos D. Korczyn
Background and Purpose—: Poststroke cognitive impairment is a debilitating consequence of stroke. The aim of this study was to assess whether Actovegin confers cognitive benefit in patients who have had an ischemic stroke. Methods—: This was a 12-month, parallel-group, randomized, multicenter, double-blind, placebo-controlled study. Eligible patients were ≥60 years of age with a Montreal Cognitive Assessment test score of ≤25 points. Patients were randomized into 2 groups within 1 week of acute supratentorial ischemic stroke in a 1:1 ratio: Actovegin (a deproteinized hemoderivative of calf blood, 2000 mg/d for ≤20 intravenous infusions followed by 1200 mg/d orally) or placebo for 6 months. Patients were treated in accordance with standard clinical practice for a further 6 months. The primary end point was the change from baseline in Alzheimer’s Disease Assessment Scale, cognitive subscale, extended version at 6 months. Results—: Two-hundred forty-eight patients were randomized to Actovegin and 255 patients to placebo. At month 6, the least squares mean change from baseline in Alzheimer’s Disease Assessment Scale, cognitive subscale, extended version was −6.8 for Actovegin and −4.6 for placebo; the estimated treatment difference was −2.3 (95% confidence interval, −3.9, −0.7; P =0.005). Recurrent ischemic stroke was the most frequently reported serious adverse event, with a nonsignificantly higher number for Actovegin versus placebo. Conclusions—: Actovegin had a beneficial effect on cognitive outcomes in patients with poststroke cognitive impairment. The safety experience was consistent with the known safety and tolerability profile of the drug. These results warrant confirmation in additional robustly designed studies. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01582854.

1 March 2007 in Neuroscience and Behavioral Physiology
Verified
Journal Article
Closed access
PDF file
NYN. N. Yakhno
N. N. Yakhno
VZV. V. Zakharov
V. V. Zakharov
ALA. B. Lokshina
A. B. Lokshina

15 March 2021 in Systemic Hypertension
Verified
Journal Article
Open access
PDF file
OOOlga D. Ostroumova
Olga D. Ostroumova
VPVladimir Parfenov
Vladimir Parfenov
TOTatiana M. Ostroumova
Tatiana M. Ostroumova
NYNikolay N. Yakhno
Nikolay N. Yakhno
ICIrina E. Chazova
Irina E. Chazova
ШВШих Евгения Валерьевна
Ших Евгения Валерьевна
Arterial hypertension (AH) is the major modifiable risk factor for cognitive impairment (CI), including dementia, CI in cerebrovascular and neurodegenerative diseases, including Alzheimers disease. By 2050, the number of people with dementia will approximately 3 times increase due to the aging population and limited opportunities for drug prevention and treatment of severe CI. In connection with the above, it seems necessary to create an expert consensus, which would summarize the evidence-based medicine data available to date on the effect of antihypertensive therapy (AHT) on cognitive function (CF). In the expert consensus, the data of prospective randomized clinical trials, observational and population studies, meta-analyzes on the effect of AHT on the risk of dementia and CI progression, including certain CF, were summarized and analyzed. The consensus considers the effect of antihypertensive drugs (AHD) on various cognitive domains. Literature data give evidence that AHT reduces the risk for dementia, including vascular dementia, reduces the risk of for dementia in Alzheimers disease, as well as reduces the risk and can prevent the progression of non-dementia CI. The effect of AHT on various CF has been little studied. Most meta-analyzes did not reveal the benefits of any class of AHD; however, one study demonstrated the advantage of angiotensin receptor blockers, while another study diuretics. The consensus emphasizes that, given the high incidence of AH in the general population, AHT may be one of the most effective ways to prevent CI or delay CI progression. The effect of different classes of AHD on CF requires further study. It is necessary to conduct a larger number of well-designed randomized clinical trials that would assess the state of executive functions in patients with AH.

1 March 2001 in Neuroscience and Behavioral Physiology
Verified
Journal Article
Closed access
PDF file
VZV. V. Zakharov
V. V. Zakharov
TAT. V. Akhutina
T. V. Akhutina
NYN. N. Yakhno
N. N. Yakhno

22 June 2024 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
KSK. V. Shevtsova
K. V. Shevtsova
DRD. O. Rozhkov
D. O. Rozhkov
DGD. A. Grishina
D. A. Grishina
VGVladislav Griniuk
Vladislav Griniuk
VZV. V. Zakharov
V. V. Zakharov
VPV. A. Parfenov
V. A. Parfenov
Diagnostic hypothesis of Alzheimer's disease (AD) is based on the typical clinical picture of the disease and the exclusion of other diseases manifesting by cognitive and behavioural disorders by MRI scans of the brain and laboratory tests. For an accurate diagnosis of AD and exclusion of other diseases, detection of biological markers (biomarkers) of AD in the cerebrospinal fluid (CSF) is of great importance: a decrease in the level of beta-amyloid (Ав^ -42) and an increase in the level of phosphorylated tau protein. The analysis of AD biomarkers in the CSF of 63 patients (16 men and 47 women, mean age 72±8.7 years) with a typical picture of AD [30 patients in the moderate cognitive impairment (MCI) stage and 33 in the mild dementia stage] allowed us to confirm the diagnosis in 54 cases (85.3%) and to exclude it in the remaining nine patients (14.7%). We present a case of a 59-year-old patient with MCI in whom biomarkers typical of AD were detected in the CSF, confirming the diagnosis of AD. We also present the observations of two patients with possible AD, in whom the results of the CSF examination made it possible to rule out AD and indicated hippocampal sclerosis and tauopathy. At present, an accurate diagnosis of AD based on the study of biomarkers of the disease is of great practical importance, since at the stage of MCI and mild dementia it is possible to prevent the progression of AD with anti-amyloid therapy. Currently, AD is rarely diagnosed in our country, so it is of great importance to inform physicians about modern methods of diagnosis and treatment of AD.